Current Report Filing (8-k)
November 13 2019 - 4:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): November 11, 2019
DERMIRA, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36668
|
|
27-3267680
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
|
|
275 Middlefield Road, Suite 150
Menlo Park, California
|
|
94025
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650)
421-7200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2 below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.001 par value
|
|
DERM
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On November 11, 2019, following the recommendation of the
nominating and corporate governance committee of the Board of Directors (the “Board”) of Dermira, Inc. (the “Company”), the Board increased the size of the Board from nine to 10 directors and elected
Halley Gilbert to fill the newly created directorship as a Class II director to hold office for a term expiring at the Company’s 2022 annual meeting of the stockholders, which is the next stockholder meeting at which Class II
directors will be elected.
In connection with her service as a director, Ms. Gilbert will receive the Company’s standard non-employee director cash and equity compensation. Ms. Gilbert will receive a $40,000 annual retainer for her service as a director, which will be pro-rated for calendar
year 2019. In connection with her election to the Board, Ms. Gilbert was granted a nonqualified stock option to purchase 20,000 shares of the Company’s common stock (the “Option”). The exercise price per share
underlying the Option was $8.05, the closing price of the Company’s common stock on November 11, 2019, the date on which Ms. Gilbert was appointed to the Board and the Board granted the Option. The Option will vest ratably over three
years, with one-third of the shares vesting on each anniversary of the grant date, for so long as Ms. Gilbert serves as a director of the Company. The Option is subject to the terms and conditions of the
Company’s 2014 Equity Incentive Plan and its related grant agreements. Ms. Gilbert will be eligible for additional grants under the Company’s director compensation policy beginning in 2020.
In addition, Ms. Gilbert has signed the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit
10.1 to the Company’s Registration Statement on Form S-1/A (File No. 333-198410) filed with the Securities and Exchange Commission on September 19, 2014
and incorporated by reference herein.
There are no arrangements or understandings between Ms. Gilbert and any other persons pursuant
to which she was selected as a member of the Board. There are also no family relationships between Ms. Gilbert and any director or executive officer of the Company, and Ms. Gilbert does not have a direct or indirect material interest in
any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
A copy of the
press release announcing this event is filed as Exhibit 99.1 to this Current Report on Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
DERMIRA, INC.
|
|
|
|
|
|
|
Date: November 13, 2019
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Andrew L. Guggenhime
|
|
|
|
|
|
|
|
Name: Andrew L. Guggenhime
|
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2023 to Apr 2024
